Latest Funding News

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

West Cobar Metals reports significant progress across its WA and NSW projects, with promising assay results for rare earths and base metals, alongside strategic engagement in the US market and a recent $1.25 million capital raise.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Prairie Lithium has fast-tracked its flagship Saskatchewan lithium project by initiating fabrication of a commercial-scale extraction unit and securing vital rail access, supported by a US$5 million non-dilutive capital raise and a promising offtake agreement.

Xstate Resources has secured $3.82 million through a two-tranche capital raising to advance appraisal and production testing at its Diona-1 well in Queensland, positioning the company for critical flow testing and further exploration.

Livium Ltd has completed its strategic pivot to focus on recycling clean energy waste, reporting solid Q1 FY26 results and securing a significant capital raise to fuel expansion into battery, solar panel, and rare-earth element recycling.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.

Top End Energy has unveiled a significant prospective hydrogen resource in Kansas and strengthened its U.S. market presence with new OTCQB listings, while advancing strategic discussions in Australia’s Beetaloo Basin.